TY - JOUR
T1 - Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134)
AU - Petty, John K.
AU - He, Ken
AU - Corless, Christopher L.
AU - Vetto, John T.
AU - Weinberg, Andrew D.
PY - 2002
Y1 - 2002
N2 - Background: The T-cell costimulatory molecule OX-40 (CD134) is expressed on activated CD4+ ("helper") T cells. Such cells have been detected in human cancers, and engagement of OX-40 improves colon cancer immunity in an animal model. Methods: Sections of primary colon cancers, normal margins, mesenteric lymph nodes, and metastases were stained for OX-40 by immunohistochemistry. Cancer registry data were reviewed. Results: High levels of OX-40 positive tumor-infiltrating lymphocytes were found in 15 of 72 primary tumors. Thirty-one cases had prominent lymphocytic infiltrates expressing OX-40 at the invasive margin of the tumor. Overall, 50% of primary tumors showed high expression of OX-40. Nearly all mesenteric lymph nodes expressed OX-40, whether tumor was present or not. Normal margins of colon did not show high levels of OX-40. High OX-40 expression in the primary tumor correlated with better survival (mean survival high OX-40, 47 months, low OX-40, 35 months, P <0.05), although this correlation was not stage-independent. Conclusions: High levels of OX-40 positive lymphocytes are present in half of primary colon cancers, and this expression in primary tumors significantly correlates with better survival. This correlation with survival and our previous preclinical research suggest a basis for an OX-40 immunotherapy trial.
AB - Background: The T-cell costimulatory molecule OX-40 (CD134) is expressed on activated CD4+ ("helper") T cells. Such cells have been detected in human cancers, and engagement of OX-40 improves colon cancer immunity in an animal model. Methods: Sections of primary colon cancers, normal margins, mesenteric lymph nodes, and metastases were stained for OX-40 by immunohistochemistry. Cancer registry data were reviewed. Results: High levels of OX-40 positive tumor-infiltrating lymphocytes were found in 15 of 72 primary tumors. Thirty-one cases had prominent lymphocytic infiltrates expressing OX-40 at the invasive margin of the tumor. Overall, 50% of primary tumors showed high expression of OX-40. Nearly all mesenteric lymph nodes expressed OX-40, whether tumor was present or not. Normal margins of colon did not show high levels of OX-40. High OX-40 expression in the primary tumor correlated with better survival (mean survival high OX-40, 47 months, low OX-40, 35 months, P <0.05), although this correlation was not stage-independent. Conclusions: High levels of OX-40 positive lymphocytes are present in half of primary colon cancers, and this expression in primary tumors significantly correlates with better survival. This correlation with survival and our previous preclinical research suggest a basis for an OX-40 immunotherapy trial.
KW - Colorectal cancer
KW - Human
KW - Immunotherapy
KW - OX-40 (CD134)
KW - T cell
UR - http://www.scopus.com/inward/record.url?scp=0036273628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036273628&partnerID=8YFLogxK
U2 - 10.1016/S0002-9610(02)00831-0
DO - 10.1016/S0002-9610(02)00831-0
M3 - Article
C2 - 12034383
AN - SCOPUS:0036273628
SN - 0002-9610
VL - 183
SP - 512
EP - 518
JO - American journal of surgery
JF - American journal of surgery
IS - 5
ER -